Neuroendocrine Tumors Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Neuroendocrine tumors pipeline drugs market report includes an assessment of the disease epidemiology, the leading marketed products with sales forecasts, late-to-mid-stage pipeline products with phase transition success rate (PTSR), and likelihood of approval (LoA) for neuroendocrine tumors (NET). The report also analyzes the clinical and commercial landscapes of NET, as well as an assessment of deals, future market catalysts, key market players, and the future competitive environment.
Neuroendocrine neoplasms (NENs) are a group of rare, heterogeneous tumors that can develop sporadically in many different organs of the body and arise from specialized cells of the nervous and endocrine system called the neuroendocrine cells.
Which are the key regions in the Neuroendocrine tumors pipeline drugs market?
The key regions in the Neuroendocrine tumors pipeline drugs market are Asia-Pacific, Europe, Middle East & Africa, North America, South & Central America. Single-country trials for NET were active mostly in the northern hemisphere, with the highest number of trials conducted in North America.
Neuroendocrine tumors pipeline drugs market, by regions
For more region insights, download a free report sample
Which are the key stages of development in the Neuroendocrine tumors pipeline drugs market?
The key stages of development in the Neuroendocrine tumors pipeline drugs market are pre-registration, phase I, phase II, phase III, preclinical, discovery, and IND/CTA filed. Phase II has the highest share in the Neuroendocrine tumors pipeline drugs market.
Neuroendocrine tumors pipeline drugs market, by development stages
For more development stage insights, download a free report sample
Which are the key MoA in the Neuroendocrine tumors pipeline drugs market?
The key MoA in the Neuroendocrine tumors pipeline drugs market are enzyme inhibitor, receptor antagonist, receptor agonist, cytotoxic, protein and peptide inhibitor, receptor inhibitor, protein and peptide activator, transporter activator, transporter inhibitor and others. Enzyme inhibitor has the highest share in the Neuroendocrine tumors pipeline drugs market.
Neuroendocrine tumors pipeline drugs market, by MoA
For more MoA insights, download a free report sample
Which are the key RoA in the Neuroendocrine tumors pipeline drugs market?
The key RoA in the Neuroendocrine tumors pipeline drugs market are injection, oral, topical, and inhalation. Injection has the highest share in the Neuroendocrine tumors pipeline drugs market.
Neuroendocrine tumors pipeline drugs market, by RoA
For more RoA insights, download a free report sample
Which are the key molecule types in the Neuroendocrine tumors pipeline drugs market?
The key molecule types in the Neuroendocrine tumors pipeline drugs market are biologic, small molecule, oligonucleotide. Biologic has the highest share in the Neuroendocrine tumors pipeline drugs market.
Neuroendocrine tumors pipeline drugs market, by molecule types
For more molecule type insights, download a free report sample
Which are the key sponsors in the Neuroendocrine tumors pipeline drugs market?
The key sponsors in the Neuroendocrine tumors pipeline drugs market are National Cancer Institute US, Hutchison Medipharma Ltd, Pecking University, Novartis AG, F. Hoffman-La Roche Ltd, Ipsen SA, and others. The National Cancer Institute US has sponsored the highest number of clinical trials.
Neuroendocrine tumors pipeline drugs market, by sponsors
To know more about sponsors, download a free report sample
Market report overview
Key Regions | Asia-Pacific, Europe, Middle East & Africa, North America, South & Central America |
Key MoA | Enzyme Inhibitor, Receptor Antagonist, Receptor Agonist, Cytotoxic, Protein And Peptide Inhibitor, Receptor Inhibitor, Protein And Peptide Activator, Transporter Activator, Transporter Inhibitor and Others |
Key RoA | Injection, Oral, Topical, and Inhalation |
Key Molecule Types | Biologic, Small Molecule, Oligonucleotide |
Key Development Stage | Pre-Registration, Phase I, Phase II, Phase III, Preclinical, Discovery and IND/CTA Filed |
Key sponsors | National Cancer Institute US, Hutchison Medipharma Ltd, Pecking University, Novartis AG, F. Hoffman-La Roche Ltd, Ipsen SA, and others |
Scope
GlobalData’s Neuroendocrine Tumors Marketed and Pipeline Drugs Assessment, Clinical Trials, Social Media and Competitive Landscape, 2022 Update combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type and Route of Administration
- Product Profiles with Sales Forecast
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the Neuroendocrine tumors market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Neuroendocrine tumors market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
Which are the key regions in the Neuroendocrine tumors pipeline drugs market?
The key regions in the Neuroendocrine tumors pipeline drugs market are Asia-Pacific, Europe, Middle East & Africa, North America, South & Central America.
-
Which are the key stages of development in the Neuroendocrine tumors pipeline drugs market?
The key stages of development in the Neuroendocrine tumors pipeline drugs market are pre-registration, phase I, phase II, phase III, preclinical, discovery and IND/CTA filed.
-
Which are the key MoA in the Neuroendocrine tumors pipeline drugs market?
The key MoA in the Neuroendocrine tumors pipeline drugs market are enzyme inhibitor, receptor antagonist, receptor agonist, cytotoxic, protein and peptide inhibitor, receptor inhibitor, protein and peptide activator, transporter activator, transporter inhibitor and others. Enzyme inhibitor has the highest share in the Neuroendocrine tumors pipeline drugs market.
-
Which are the key RoA in the Neuroendocrine tumors pipeline drugs market?
The key RoA in the Neuroendocrine tumors pipeline drugs market are injection, oral, topical, and inhalation. Injection has the highest share in the Neuroendocrine tumors pipeline drugs market.
-
Which are the key molecule types in the Neuroendocrine tumors pipeline drugs market?
The key molecule types in the Neuroendocrine tumors pipeline drugs market are biologic, small molecule, oligonucleotide.
-
Which are the key sponsors in the Neuroendocrine tumors pipeline drugs market?
The key sponsors in the Neuroendocrine tumors pipeline drugs market are National Cancer Institute US, Hutchison Medipharma Ltd, Pecking University, Novartis AG, F. Hoffman-La Roche Ltd, Ipsen SA, and others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.